In MDA-MB-435 breast cancer cells, cotreatment of doxorubicin with TSN can significantly enhance the anti-breast cancer activity, and the mechanism may depend on the FoxO1-Bim/Noxa pathway. This evidence concerns the gene FOXO1 and breast cancer.